Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "WHO"

2991 News Found

Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer
Drug Approval | February 27, 2026

Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer

BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results


Alembic Pharma secures USFDA approval for generic Lamotrigine orally disintegrating tablets
Drug Approval | February 26, 2026

Alembic Pharma secures USFDA approval for generic Lamotrigine orally disintegrating tablets

The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder


CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC
Clinical Trials | February 25, 2026

CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC

Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity


Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
News | February 25, 2026

Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ

The innovative eyedrop targets inflammation and pain following ocular surgery


Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
Clinical Trials | February 25, 2026

Novo Nordisk unveils weight-loss data from REDEFINE 4 trial

CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide


UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
News | February 25, 2026

UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis

NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production


ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
Biopharma | February 24, 2026

ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients

To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia


Bayer introduces chemo-free treatment option for advanced prostate cancer in India
News | February 24, 2026

Bayer introduces chemo-free treatment option for advanced prostate cancer in India

Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year